IP Library Granted Patent US 10,822,394
Granted Patent B2
US 10,822,394 · App. 16/125,141 · Granted Nov 3, 2020

Method of producing recombinant high molecular weight vWF in cell culture

Inventors: Leopold Grillberger (Vienna, AT); Manfred Reiter (Vienna, AT); Wolfgang Mundt (Vienna, AT)
Assignees: Baxalta GmbH; Baxalta Incorporated
C07K14/755A61K9/0019A61K38/36A61K38/37C12N9/6489C12P21/00A61K38/00C12N2500/24C12N2511/00C12Y304/24087
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,822,394
App. No.
16/125,141
Granted
Nov 3, 2020
Kind
B2
Abstract

Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH 4 + ) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.

Claims (43)

1. A recombinant Von Willebrand Factor (rVWF) composition comprising isolated soluble rVWF, wherein the composition has a NH4+ concentration of below 4 mM or below 10 mM, wherein the composition contains at least 0.5 IU ristocetin cofactor activity per mL, and wherein the composition is prepared by a method comprising the steps of:

(a) providing a basal cell culture media;

(b) supplementing the basal cell culture media with copper to provide a final copper concentration of at least 2.4 μg/L;

(c) providing one or more cells comprising a nucleic acid encoding a rVWF protein;

(d) culturing the one or more cells in the copper supplemented cell culture media such that rVWF is expressed and excreted from the cells into a culture supernatant and the NH4+ content of the cell culture supernatant is remains at a concentration below 4 mM or below 10 mM; and

(e) recovering at least a portion of the culture supernatant, wherein at least 20% of the isolated soluble rVWF in the composition is present in a high molecular weight VWF multimer of more than 10 dimers.

2. The rVWF composition of claim 1 , further comprising the step of supplementing the basal cell culture media with a hydrolysate prior to culturing the one or more cells.

3. The rVWF composition of claim 2 , wherein the hydrolysate is a plant hydrolysate.

4. The rVWF composition of claim 3 , wherein the hydrolysate is a soy hydrolysate.

5. The rVWF composition of claim 1 , wherein the basal cell culture media is an animal protein free culture media.

6. The rVWF composition of claim 1 , wherein the basal cell culture media is a protein free culture media.

7. The rVWF composition of claim 1 , wherein the basal cell culture media is a chemically defined culture media.

8. The rVWF composition of claim 1 , wherein the final copper concentration of the copper supplemented basal cell culture media is at least 4 μg/L copper.

9. The rVWF composition of claim 1 , wherein the final copper concentration of the copper supplemented basal cell culture media is between 2.4 μg/L and 20 μg/L copper.

10. The rVWF composition of claim 1 , wherein the copper supplementing the basal cell culture media is provided as a copper salt, a copper chelate, or a combination thereof.

11. The rVWF composition of claim 10 , wherein the copper salt is selected from the group consisting of copper sulfate, copper acetate, copper carbonate, copper chloride, copper hydroxide, copper nitrate, and copper oxide.

12. The rVWF composition of claim 1 , wherein the one or more cells are mammalian cells.

13. The rVWF composition of claim 12 , wherein the mammalian cells are CHO cells.

14. The rVWF composition of claim 1 , wherein culturing the one or more cells comprises batch cultivation of the cells.

15. The rVWF composition of claim 1 , wherein culturing the one or more cells comprises continuous cultivation of the cells.

16. The rVWF composition of claim 15 , wherein the continuous cultivation of cells is performed in chemostatic mode.

17. The rVWF composition of claim 15 , wherein the continuous cultivation of cells is performed in perfusion mode.

18. The rVWF composition of claim 1 , wherein the one or more cells is cultured in at least 100 L of the supplemented basal cell culture media.

19. The rVWF composition of claim 1 , wherein the cell density is maintained at less than 2.5×10 6 cells per mL during the step of culturing the one or more cells.

20. The rVWF composition of claim 19 , wherein the cell density is maintained at less than 2.0×10 6 cells per mL during the step of culturing the one or more cells.

21. The rVWF composition of claim 19 , wherein the cell density is maintained at less than 1.5×10 6 cells per mL during the step of culturing the one or more cells.

22. The rVWF composition of claim 1 , wherein the step of recovering at least a portion of the culture supernatant comprises filtration or centrifugation to remove cells from the portion of culture supernatant.

23. The rVWF composition of claim 1 , wherein at least 30% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

24. The rVWF composition of claim 1 , wherein the supernatant contains high molecular weight VWF multimers of 14 to 22 dimers.

25. The rVWF composition of claim 1 , wherein rVWF is co-expressed with recombinant Factor VIII (rFVIII).

26. The rVWF composition of claim 25 , further comprising a step of purifying rVWF away from at least 50% of the rFVIII present in the recovered supernatant.

27. The rVWF composition of claim 26 , wherein the ratio of rVWF to rFVIII after the purification step is at least 10:1.

28. The rVWF composition of claim 1 , wherein the method further comprises a rVWF enrichment step.

29. The rVWF composition of claim 1 , wherein the composition is formulated for pharmaceutical administration.

30. The rVWF composition of claim 1 , wherein the composition is formulated for intravenous administration.

31. A rVWF composition comprising isolated soluble rVWF having a specific ristocetin cofactor activity of at least 40 mU/μg, wherein the composition has a NH4+ concentration of below 4 mM or below 10 mM, and wherein the composition is prepared by a method comprising the steps of:

(a) providing a basal cell culture media;

(b) supplementing the basal cell culture media with copper to provide a final copper concentration of at least 2.4 μg/L;

(c) providing one or more cells comprising a nucleic acid encoding a rVWF protein;

(d) culturing the one or more cells in the copper supplemented cell culture media such that rVWF is expressed and excreted from the cells into a culture supernatant and the NH4+ content of the cell culture supernatant remains at a concentration below 4 mM or below 10 mM; and

(e) recovering at least a portion of the culture supernatant, wherein at least 20% of the isolated soluble rVWF in the composition is present in a high molecular weight VWF multimer of more than 10 dimers.

32. The rVWF composition according to claim 1 , wherein the isolated soluble rVWF is not plasma derived VWF (pdVWF) or ultra-large VWF in Weibel-Palade bodies or Golgi apparatus.

33. The rVWF composition according to claim 31 , wherein the isolated soluble rVWF is not plasma derived VWF (pdVWF) or ultra-large VWF in Weibel-Palade bodies or Golgi apparatus.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2019
From: GRILLBERGER, LEOPOLD; REITER, MANFRED; MUNDT, WOLFGANG
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 048544/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2019
From: BAXTER INERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 048545/0061 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2019
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 048545/0636 →